Shenyang Military Region General Hospital Han Yaling and Fu Wai Hospital Xu Bo et al in the Circulation intervention published I-LOVE-IT 2 study subgroup analysis results show that the new biodegradable sirolimus drug-coated stent patients , The safety and efficacy of double antiplatelet therapy after 6 months of treatment were not inferior to that of double antiplatelet for 12 months.
The authors argue that although the current guidelines recommend acute coronary syndromes (ACS) patients who have to undergo at least one year of antiplatelet therapy after placement of the stent, but based on the findings, the investigators believe that not all of them are involved Treatment of ACS patients must undergo at least one year of double antiplatelet therapy.
For patients with high risk of bleeding or who can not tolerate long-term antiplatelet therapy, patients with double antiplatelet therapy can be selected for 6 months, and at least 6 months of postoperative 6 months Platelet therapy.
In the study, follow-up to 6 months, double antiplatelet therapy in patients with 12 months of target lesion failure rate and double antiplatelet therapy 6 months is comparable (6.8% vs 5.9%).
The incidence of target lesion failure (7.5% vs 6.3%) and the incidence of adverse clinical events and cerebrovascular events (7.8% vs 7.3%) were similar in both groups at 18 months follow-up.
The major bleeding events at 12 months and 18 months of double antiplatelet therapy were 1.2% and 1.3%, respectively, were higher than those with double antiplatelet therapy for 6 months (0.7% and 0.85, respectively) The
Subgroup analysis included 1829 ACS patients who were randomized to receive double-platelet therapy for 6 months and 12 months. (From "Physician" March 3, 2016)